תמונות העטיפה

Chronic HCV Infection: Clinical Advances and Eradication Perspectives

Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus...

תיאור מלא

שמור ב:
פורמט: Online
שפה:אנגלית
יצא לאור: MDPI - Multidisciplinary Digital Publishing Institute 2022
נושאים:
HCV
rheumatic
interferon
mortality
hepatitis C virus (HCV)
phylogeny
resistance-associated substitution (RAS)
chronic hepatitis C
vibration controlled transient elastography
fibrosis
steatosis
hepatocellular carcinoma
hepatitis C
genotype 3
liver cirrhosis
pangenotypic
children
ledipasvir/sofosbuvir
real-life
sustained virological response
elimination
model
COVID-19
PWID
homeless persons
HCV eradication
direct-acting antivirals
out-of-hospital
retention in care
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics
גישה מקוונת:ONIX_20220321_9783036533612_111
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
סיכום:Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus screening policy in the general population and in specific risk categories is necessary to allow for timely intervention. Despite a high sustained virological response by direct-acting antiviral drugs, a limited percentage of treated subject failed therapy according to resistance associated substitution carried on viral isolates and comorbidities in infected patients. Therefore, tailored therapy is required to cure HCV infection. Failure to comply with these conditions may impair success of HCV eradication expected by 2030. This Special Issue aims to discuss eradication perspectives related to therapy efficacy in patients with chronic diseases, developments in diagnostic procedures and improvements in screening policy.

פריטים דומים